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An  imbalance  in all-cause  mortality  was  noted  in tigecycline  phase  3 and 4 comparative  clinical  trials
across  all  studied  indications.  We  investigated  clinical  failure  and mortality  in  phase  3 and 4 complicated
skin  and  soft-tissue  infection  (cSSTI)  and  complicated  intra-abdominal  infection  (cIAI)  tigecycline  trials
using descriptive  analyses  of  a blinded  adjudication  of mortality  and  multivariate  regression  analyses.
Attributable  mortality  analyses  of cSSTI  revealed  death  due  to infection  in 0.1% of each  treatment  group
(P  =  1.000).  In cIAI,  there  were  no  signiﬁcant  differences  between  tigecycline  (1.2%)  and  comparator  (0.7%)
subjects who  died  due  to infection  (P = 0.243).  For  cIAI clinical  failure,  treatment  interaction  with  organ
dysfunction  was  observed  with  no  difference  observed  between  clinical  cure  for tigecycline  (85.4%)  andisk factor comparator  (76.7%)  treatment  groups  (odds  ratio  =  0.58,  95%  conﬁdence  interval  0.28–1.19).  Tigecycline-
treated  subjects  had  more  adverse  events  of secondary  pneumonias  (2.1%  vs. 1.2%)  and  more  adverse
events  of  secondary  pneumonias  with  an  outcome  of  death  (0.5%  vs.  0.1%).  These  analyses  do not  suggest
that  tigecycline  is a factor either  for failure  (cSSTI  and  cIAI studies)  or for death  (cIAI  studies).
©  2015  The  Authors.  Published  by  Elsevier  B.V.  on  behalf  of  International  Society of  Chemotherapy.
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. Introduction
An imbalance in all-cause mortality has been noted in tigecy-
line phase 3 and 4 comparative clinical trials across most studied
ndications, including the non-approved indications [hospital-
cquired pneumonia (HAP), including ventilator-associated pneu-
onia, and diabetic foot infection studies] [1,2]. Deaths were
ttributed to infection (i.e. worsening or complications of the infec-
ion) or underlying co-morbidities [2]. A phase 2 trial examining
igher doses for the treatment of HAP suggested that the dose of
igecycline may  have played a role in the poor clinical responses
 Portions of this work were presented at the 23rd European Congress of Clinical
icrobiology and Infectious Diseases (ECCMID), 27–30 April 2013, Berlin, Germany
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924-8579/© 2015 The Authors. Published by Elsevier B.V. on behalf of International Soci
icense (http://creativecommons.org/licenses/by-nc-nd/4.0/).nder  the  CC BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
in the previously conducted phase 3 HAP trial [3,4]. Different
published meta-analyses of study-level data suggest decreased
clinical efﬁcacy as a possible explanation for this imbalance in mor-
tality [5,6].
In this analysis, clinical failure and mortality in complicated skin
and soft-tissue infection (cSSTI) and complicated intra-abdominal
infection (cIAI) were explored using descriptive analyses of a
blinded adjudication of mortality and multivariate regression anal-
yses. The analyses were used to investigate the association of
baseline factors, including severity of illness at study entry and
treatment assignment, with clinical failure and mortality.
2. Methods
2.1. StudiesTigecycline was  given as a 100 mg  loading dose, followed by
50 mg  every 12 h for a maximum of 14 days in all studies. Com-
parator treatments varied by study and infection type [7–14].
ety of Chemotherapy. This is an open access article under the CC BY-NC-ND
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were assessed as having confounding factors (P = 0.001). Con-
founding factors in the tigecycline group included septic shock at
enrolment (n = 6), inadequate source control (n = 8) and untreated
candidiasis (n = 1). Confounding factors in the comparator group
Table 1
Attributable mortality analysis: relationship of death and infection.
Tigecycline
[n/n (%)]
Comparator
[n/n (%)]
P-valuea
cSSTI (N = 1647)
Death due to infection 1/834 (0.1) 1/813 (0.1) 1.000
Confounding factor 1/1 (100)b 0/1 (0.0) 1.000
Death with infection 2/834 (0.2) 0/813 (0.0) 0.500
Death not due to infection 9/834 (1.1) 5/813 (0.6) 0.422
cIAI (N = 2775)c
Death due to infection 16/1382
(1.2)
10/1393
(0.7)
0.243
Confounding factor 14/16
(87.5)d
2/10 (20.0)e 0.001
Death with infection 6/1382 (0.4) 1/1393 (0.1) 0.068
Death not due to infection 15/1382
(1.1)
20/1393
(1.4)
0.497
cSSTI, complicated skin and-soft tissue infection; cIAI, complicated intra-abdominal
infection.
a Fisher’s exact test (two-tailed).
b Septic shock at enrolment and myocardial infarction.M. Bassetti et al. / International Journa
.2. Analysis methods
Several analyses including attributable mortality analysis and
ogistic regression were conducted to understand and evaluate the
mbalance in mortality.
.2.1. Attributable mortality
Medical records of subjects who died in the cSSTI and cIAI
rials were reviewed by three independent experts. The spon-
or provided blinded subject narratives pertaining to the death
f the study subjects. Subject narratives included: demographic
ata; relevant medical history, including initial symptoms and
linical process leading to study inclusion; concomitant medi-
ation use; dates of study drug administration; adverse event
AE) information; Acute Physiology and Chronic Health Evalu-
tion (APACHE) II score (cIAI only) at study inclusion; clinical
isease course and relevant microbiology; and laboratory data.
eath certiﬁcates and available autopsy results also were pro-
ided.
Individual expert judgement was applied to attribute the cause
f death. Deaths were categorised into predeﬁned categories: (i)
eath due to infection—death was related to the primary infec-
ion; possible treatment failure; (ii) death not due to primary
nfection—e.g. an AE; and (iii) death with infection—death was
nrelated to the primary infection but occurred while under-
oing treatment. The individual reviewer was blinded to the
djudications of the other reviewers. For ﬁnal categorisation, agree-
ent on the classiﬁcation between at least two  reviewers was
eeded. If a consensus was not reached, the data were excluded.
ollowing the review process, the results were aggregated and
nblinded.
.2.2. Multivariate logistic regression
Multivariate logistic regression was used to identify factors in
ach infection type that were signiﬁcantly related to clinical failure
n the clinically evaluable (CE) population. An analysis to identify
actors related to mortality in the modiﬁed intent-to-treat (mITT)
opulation (i.e. subjects receiving at least one dose of study drug)
as performed.
Clinical response deﬁnitions were based on the clinical trial def-
nitions in each protocol [7–14]. Baseline factors included in the
nalyses were demographics, medical history, infection and surgi-
al variables, laboratory parameters and severity of infection, and
he subject’s condition at enrolment. For the cIAI analysis, organ
ysfunction at baseline, deﬁned as creatinine >2.0 mol/L, inter-
ational normalised ratio >1.5 or activated partial thromboplastin
ime >60 s, platelets <100,000 109/L and total bilirubin >70 mol/L
not used for subjects with complicated cholecystitis), was  also
valuated.
Potential interactions between treatment and each of the
ovariates of interest were evaluated in univariate models with
utcomes of failure and mortality. Interactions that met  the
creening criteria of a P-value of <0.05 were chosen for inclu-
ion in the ﬁnal model-building process. A bootstrap approach
as used to select variables for the ﬁnal model [15]. Variables
ere identiﬁed for inclusion in the ﬁnal model based on selec-
ion in ≥50% of 1000 bootstrap samples, where the model for
ach bootstrap sample was selected by backward variable elimi-
ation..2.3. Adverse events
Using the clinical safety database, pneumonia AEs and seri-
us AEs associated with mortality were descriptively compared
etween treatment arms.timicrobial Agents 46 (2015) 346–350 347
2.3. Ethics
This was  a secondary analysis of clinical trials; detailed insti-
tutional review board approval and informed consent were not
applicable.
3. Results
A total of 2216 subjects received tigecycline (cSSTI, n = 834; cIAI,
n = 1382) and 2206 received a comparator treatment (cSSTI, n = 813;
cIAI, n = 1393).
3.1. Attributable mortality
Of the 91 deaths evaluated, there were 54 deaths in the tigecy-
cline group and 37 in the comparator group. In the cSSTI trials, there
were 18 deaths, with 12 deaths occurring in the tigecycline group
and 6 in the comparator group. In the cIAI trials, 42 deaths occurred
with tigecycline and 31 with comparator treatment. A consensus
could not be reached in ﬁve cases; these deaths were excluded
from further analysis before unblinding. After blinding was  bro-
ken, it was determined that all ﬁve cases were in the tigecycline
cIAI treatment group.
A summary of the attributable mortality classiﬁcations is shown
in Table 1. For the cSSTI indication, the majority of tigecycline and
comparator cases were not attributed to infection. One case in each
treatment group was  due to infection; the tigecycline case was
associated with septic shock at enrolment and myocardial infarc-
tion.
For the cIAI indication, differences between treatment groups
were observed in the classiﬁcation schema. A greater number of
comparator-treated subjects died not due to infection (1.4% vs.
1.1%; P = 0.497) and a greater number of tigecycline-treated sub-
jects died with infection (0.4% vs. 0.1%; P = 0.068). A numerically
higher number of tigecycline-treated subjects (n = 16; 1.2%) than
comparator-treated subjects (n = 10; 0.7%) died due to infection
(P = 0.243); however, of those, more tigecycline-treated subjectsc Five missing patients in the tigecycline group represent the cases where there
was  no agreement among the adjudicators; these patients were excluded from the
analysis.
d Septic shock at enrolment, inadequate source control and untreated candidiasis.
e Septic shock at enrolment and inadequate source control.
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Table 2
Multivariate logistic regression modelling in subjects with complicated skin and-soft tissue infection (cSSTI) and complicated intra-abdominal infection (cIAI).
Variable Adjusted OR 95% CI P-value
Clinical failure (CE population)
cSSTI
History of diabetes 1.93 1.35–2.77 <0.001
Haemoglobin 0.89 0.82–0.98 0.012
Elevated WBC  count 1.54 1.14–2.07 0.005
Total  protein 0.87 0.74–1.02 0.086
Region (vs. Asia)
South America 0.31 0.14–0.69 <0.001
North America 0.87 0.50–1.49 <0.001
India 0.48 0.21–1.09 <0.001
Europe 0.37 0.21–0.65 <0.001
cIAI
APACHE II score 1.90 1.36–2.66 <0.001
Baseline AST/ALT >ULN 1.25 0.93–1.68 0.132
BMI  1.45 1.11–1.89 0.006
Total  protein 0.82 0.71–0.94 0.004
Source of infection (vs. appendix)
Gallbladder 0.29 0.15–0.55 <0.001
Intra-abdominal abscess 1.26 0.75–2.12 <0.001
Large  bowel 1.47 1.00–2.18 <0.001
Small  bowel 1.16 0.67–2.02 <0.001
Stomach/duodenum 0.68 0.37–1.25 <0.001
Increased probability of controlling source infectiona 0.73 0.62–0.86 <0.001
Size  of abscessb 1.13 1.00–1.28 0.046
Nosocomial infection 1.57 0.95–2.60 0.082
ICU within 24 h after surgery 1.51 1.07–2.12 0.018
Baseline vasopressor use 1.45 0.71–2.99 0.309
Type  of surgery 0.77 0.61–0.96 0.023
Non-susceptible Gram-negative pathogenc 2.07 1.09–3.90 0.025
Non-susceptible anaerobic pathogen 1.78 1.11–2.85 0.018
Presence of Enterococcus spp. 1.43 0.99–2.07 0.055
Mortality (cIAI mITT population)
Age (years) 1.76 1.46–2.11 <0.0001
Total  protein 0.70 0.55–0.88 0.003
Source of infection (vs. appendix)
Gall bladder 0.61 0.15–2.49 0.001
Intra-abdominal abscess 2.82 0.95–8.39 0.001
Large  bowel 4.60 1.79–11.83 0.001
Small bowel 6.27 2.22–17.71 0.001
Stomach/duodenum 3.31 1.14–9.63 0.001
Increased probability of controlling source infectiona 0.69 0.53–0.89 0.005
Size  of abscessb 1.27 1.01–1.59 0.041
ICU  within 24 h after surgery 1.85 1.02–3.37 0.044
Baseline vasopressor use 2.57 1.23–5.37 0.012
OR, odds ratio; CI, conﬁdence interval; CE, clinically evaluable; WBC, white blood cell; APACHE, Acute Physiology and Chronic Health Evaluation; AST, aspartate aminotrans-
ferase;  ALT, alanine aminotransferase; ULN, upper limit of normal; BMI, body mass index; ICU, intensive care unit; mITT, modiﬁed intent-to-treat.
a 1, <25%; 2, 25–49%; 3, 50–74%; 4, 75–95%; and 5, >95%.
i
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yb 0, no abscess; 1, <10 mL;  2, 10–100 mL;  and 3, >100 mL.
c Excludes Pseudomonas spp.
ncluded septic shock at enrolment (n = 1) and inadequate source
ontrol (n = 1). Confounding factors, in particular septic shock and
nadequate surgical source control, suggested a further examina-
ion of baseline characteristics, including severity at presentation.
.2. Multivariate logistic regression
.2.1. Complicated skin and soft-tissue infection
A total of 1238 CE subjects (tigecycline, n = 631; compara-
or, n = 607) from three cSSTI trials were included in the clinical
esponse modelling. Subjects had similar baseline demographics
Supplementary Table S1). Clinical diagnosis was similar between
roups, with the majority of infections attributed to deep soft-
issue infection.
Supplementary Table S1 related to this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.ijantimicag.2015.
5.012
A failure model was run on the CE populations. The initial anal-
sis evaluated treatment, 23 additional variables (SupplementaryTable S2) and three treatment interactions [presence of fever, ele-
vated white blood cell (WBC) count and presence of Gram-negative
pathogens (except Pseudomonas aeruginosa)]. Following backward
elimination in 1000 bootstrap re-samples, eight variables remained
(history of diabetes, diagnosis, presence of fever, haemoglobin,
total protein, region, treatment and elevated WBC  count). Due to
model convergence issues, the model was  then further reduced by
repeating the bootstrapping analysis methods. The ﬁnal model was
based on selecting variables occurring with a frequency >50% and
included diabetes, haemoglobin, total protein, region and elevated
WBC  count. The ﬁnal model included these variables in addition
to forcing treatment into the model. History of diabetes (1.93) and
elevated WBC  count (1.54) were identiﬁed as variables [odds ratio
(OR)] associated with clinical failure (Table 2). Treatment was not
included in the ﬁnal model for failure by the bootstrapping process
because it was not selected as an important factor (i.e. not selected
in >50% of the models). Treatment was forced into the ﬁnal logistic
models [OR = 1.21, 95% conﬁdence interval (CI) 0.87–1.69] to give an
estimate of the treatment effect while adjusting for other important
covariates.
M. Bassetti et al. / International Journal of An
Table  3
Rates of cure by organ dysfunction in subjects with complicated intra-abdominal
infection (cIAI) (clinically evaluable population).
Variable Tigecycline
cure [n/n (%)]
Comparator
cure [n/n (%)]
OR (95% CI)a
Organ dysfunction
Yes 123/144
(85.4)
112/146
(76.7)
0.58 (0.28–1.19)
No 827/998
(82.9)
886/1013
(87.5)
1.40 (1.05–1.88)
OR, odds ratio; CI, conﬁdence interval.
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fa The OR and 95% CI obtained from ﬁnal logistic model.
Supplementary Table S2 related to this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.ijantimicag.2015.
5.012
A multivariate mortality analysis was not conducted because of
he limited number of deaths (18/1647).
.2.2. Complicated intra-abdominal infection
A total of 2309 CE subjects (tigecycline, n = 1149; comparator,
 = 1160) from ﬁve cIAI trials were included in the clinical fail-
re modelling, and 2775 subjects who received at least one dose
f study drug (tigecycline, n = 1382; comparator, n = 1393) were
ncluded in the mortality modelling. Subjects had similar baseline
emographics in the mITT population (Supplementary Table S3)
nd the CE population (data not shown). Vasopressor use at baseline
as numerically higher in the tigecycline group (54/1382; 3.9%)
ersus the comparator group (37/1393; 2.7%) (P = 0.064).
Supplementary Table S3 related to this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.ijantimicag.2015.
5.012
In the initial clinical failure model, treatment, 24 variables
Supplementary Table S4) and two treatment interactions (vaso-
ressor use and presence of organ dysfunction) were tested.
sing bootstrapping, 17 variables and one treatment interaction
ere identiﬁed for continued evaluation: non-susceptible anaer-
bic pathogen; APACHE II score; elevated liver function tests;
ody mass index; presence of a non-susceptible Gram-negative
athogen other than P. aeruginosa; nosocomial infection; organ
ysfunction; admission to the intensive care unit (ICU); vasopres-
or use; total protein; region; size of abscess; source of infection;
ecreased probability of controlling source infection as assessed
y the surgeon; antibiotic treatment; type of surgery; and treat-
ent interaction with organ dysfunction. A multivariate analysis
Table 2) identiﬁed several independent variables (OR) associated
ith clinical failure. Laparotomy was protective relative to laparo-
copic and percutaneous procedures.
Supplementary Table S4 related to this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.ijantimicag.2015.
5.012
Data regarding an organ dysfunction interaction effect with
reatment are shown in Table 3. A numerically higher number
f tigecycline-treated subjects were cured relative to comparator-
reated subjects, but the differences were not signiﬁcant (85.4% vs.
6.7%). Subjects without organ dysfunction were more likely to be
ured with comparator treatment than with tigecycline. No associa-
ion between treatment failure and vasopressor use was identiﬁed.
he vast majority of subjects in both groups were not receiving
asopressor treatment; however, tigecycline cured 27/35 subjects
77.1%) with baseline vasopressor use compared with 12/25 (48.0%)
f comparator-treated subjects.
Treatment group and the same 24 variables tested in the clini-
al failure model (Supplementary Table S4) were initially selected
or evaluation in the mortality analysis. The selection of variablestimicrobial Agents 46 (2015) 346–350 349
was narrowed to eight following bootstrap elimination: age; care
in the ICU at baseline; probability of controlling source infection;
vasopressor use; total protein; region; size of abscess; and source
of infection. No signiﬁcant treatment interactions were noted.
Independent variables (OR) associated with mortality in the mul-
tivariate analysis are listed in Table 2. Treatment was forced into
the ﬁnal logistic model (OR = 1.25, 95% CI 0.73–2.14) for mortality
to give an estimate of the treatment effect while adjusting for other
important covariates.
3.3. Adverse events
The reasons for death in subjects whose death was not related
to infection are listed in Supplementary Table S5. An evalua-
tion of the reasons for death demonstrated a numerically higher
number of deaths related to pneumonia in tigecycline-treated
subjects. Further review of the clinical safety database demon-
strated for the cSSTI indication that the overall number of subjects
who were reported as having pneumonia during the study was
4/834 (0.5%) among tigecycline-treated subjects and 1/813 (0.1%)
among comparator-treated subjects. No deaths were reported
among these subjects and three of the four tigecycline pneumo-
nias occurred after therapy completion. For the cIAI indication,
29/1382 (2.1%) tigecycline-treated subjects were reported as hav-
ing pneumonia compared with 17/1393 (1.2%) comparator-treated
subjects. Among subjects with cIAIs, death occurred in 7/1382
(0.5%) tigecycline-treated and 1/1393 (0.1%) comparator-treated
subjects reported as having pneumonia. Pneumonia developed
while on study drug in 22/29 subjects (75.9%) in the tigecycline
group and 10/17 subjects (58.8%) in the comparator group. Vomi-
ting did not appear to contribute to the development of pneumonia
on study, as only 2/29 (6.9%) tigecycline-treated and 3/17 (17.6%)
comparator-treated subjects reported vomiting before the episode
of pneumonia.
Supplementary Table S5 related to this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.ijantimicag.2015.
05.012
4. Discussion
This study provides valuable insights into clinical response,
mortality and complicating AEs. For the cSSTI indication, mul-
tivariate modelling suggested that diabetes and elevated WBC
count, but not treatment assignment, were associated with clin-
ical failure. Blinded attributable mortality analysis suggested a
low attributable fraction of subjects with cSSTI who died due
to infection. Combined with the overall demonstration of non-
inferiority with comparator treatments in three appropriately
powered studies [7,9,12], the cSSTI deaths appear related more
to the subject’s underlying co-morbid state and not due to poor
clinical response.
Similar conclusions can be drawn for the cIAI indication.
Multivariate clinical response modelling did not suggest that treat-
ment assignment was associated with clinical failure. A treatment
assignment interaction with organ dysfunction was  identiﬁed
in multivariate clinical response modelling; however, tigecycline
clinical success was  higher in subjects with organ dysfunction
and lower in those without organ dysfunction. Although base-
line vasopressor use was  not associated with clinical failure,
tigecycline-treated subjects with baseline vasopressor use had
numerically higher clinical success than comparator-treated sub-
jects. Efﬁcacy did not worsen in subjects with baseline markers
of more severe cIAI; this is counterintuitive if efﬁcacy in cIAI was
associated with mortality, as was  observed in the phase 3 HAP trial
[2,3].
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Mortality modelling identiﬁed multiple factors associated with
eath, but not tigecycline that was forced into the model. Simi-
arly, attributable mortality among subjects who died of primary
nfection in the cIAI studies showed no difference among treat-
ents. Combined with the four powered phase 3 and 4 cIAI
rials that demonstrated the non-inferiority of tigecycline to
he comparator regimens [8,10,11,13], these results suggest that
eaths were less related to clinical failure and that other fac-
ors or patient co-morbidities were more likely to contribute to
eath.
One of the most interesting cIAI observations gleaned from the
ttributable mortality analysis and safety database review was  the
bservation of more pneumonias in tigecycline-treated subjects.
here were few deaths, but a larger disparity in subjects with pneu-
onia developing between tigecycline- and comparator-treated
ubjects. Although pneumonia is a well recognised complication of
IAI, the excess number of pneumonia cases in tigecycline-treated
ubjects remains puzzling. Although speculative at best, the lack of
fﬁcacy in the phase 3 HAP trial may  suggest that tigecycline failed
o prevent or treat emergent pneumonia at the standard dose given
n cIAI [3].
The current analysis has some limitations. First, the analyses
ere post hoc and the data source was clinical trials that were not
peciﬁcally designed to answer these proposed questions. Second,
o attributable mortality classiﬁcation has been validated; how-
ver, this schema was used to better understand the subject deaths
n relation to the primary infection under treatment. Finally, the
imited number of deaths among patients with cSSTI precludes a
ultivariate mortality analysis in this population.
. Conclusions
In this study, modelling and attributable mortality analyses sug-
ested that tigecycline is not a signiﬁcant factor either for failure
cSSTI and cIAI studies) or for death (cIAI studies).
The increased medical need represented by the growing impact
f multidrug-resistant infections and the current lack of alternative
r new antibiotics suggests that tigecycline beneﬁt–risk continues
o be positive; however, the all-cause mortality difference should
e considered when using tigecycline.
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